Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 2

Status

Active not recruiting 3Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Gynecologic 1

Conditions

Breast Neoplasms 3Endometrial Neoplasms 1

Interventions

pembrolizumab 87Cyclophosphamide 75Nivolumab 55Specimen Handling 49fludarabine 48Magnetic Resonance Spectroscopy 44Carboplatin 42Biopsy 39Radiotherapy 32fludarabine phosphate 29Gemcitabine 28venetoclax 27Paclitaxel 27atezolizumab 26Ipilimumab 26Cisplatin 23Radiation 22Dexamethasone 22Radiosurgery 21durvalumab 20Rituximab 20Lenalidomide 19Temozolomide 17Bevacizumab 17Pemetrexed 16130-nm albumin-bound paclitaxel 16palbociclib 15Decitabine 15Cytarabine 15ibrutinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × Imlunestrant × Clear all
NCT05307705 2026-04-20

PIKASSO-01

Eli Lilly and Company

Phase 1 Active not recruiting
193 enrolled
Breast

Breast Neoplasms

NCT05509790 2026-04-13

A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer

Eli Lilly and Company

Phase 1 Active not recruiting
17 enrolled
Breast

Breast Neoplasms

NCT04188548 2025-06-04

EMBER

Eli Lilly and Company

Phase 1 Active not recruiting
500 enrolled
BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡